Precision Medicine for Patients With Identified Actionable Mutations
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The goal of the current pragmatic trial is to evaluate the impact of a simple method of
selecting a treatment approach for identified mutations on participants' progression free
survival (PFS). The study also intends to collect information on barriers that investigators
encounter when prescribing treatment options using the Next Generation Sequencing (NGS)
reports. Additionally, patients' quality of life will be measured before, after, and during
treatment.
Patients will be followed until death for monitoring survival study endpoints.